Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey, dr c6....thanks for keeping the board alive. Some good posts along the way but little by way of feedback. Tend to be following the Yahoo board more these days but do miss the good old days of Admiral, Silver and the like. Those were some good discussions around the hot stove but I think market forces generally, and the decline of ARYC specifically, may have driven some from their investment positions. The rest of us wait for what we all expect will be some very positive news.
Thanks Del. Good question - one or multiple?
I'm also wondering what it means when they say "for research purposes"? Methinks that it means that the test comes with strings attached. They will want to gather data on the individual to whom the test will be administered. They will wish to continue following that person if there's an anomaly discovered (or even if there's not). There will likely be follow-up testing. Would be interesting to see what the patient is actually signing up for and what the trial period is. It occurs to me that something like ovarian cancer detection is a life-long process, something like a pap smear or a mamogram - an annual event.
Nice to see some good progress.
Thanks WW for the clarification. Arrayit seems to be taking an eminently sensible approach. Using this approach, the product and procedure is introduced to as many as 1000 different doctors. The next time these specialists have a potential ovarian cancer patient, or they encounter a patient who is personally concerned about the potential for oc, who are they going to call? In a way it's a clinical trial. In another sense, it's a form of marketing, the best of both worlds.
We also know that this test goes well beyond anything currently on the market and should be out there and available. Funny thing about the FDA and their procedures. A test like CA-125 is notoriously unreliable (lots of false positives) and at best, is just a general marker. Then along comes OvaDx with a very low incidence of false anythings and a very high level of sensitivity and it takes mega testing to make sure it's "safe".
Nice to see a bounce back this morning.
Now that could be a tougher sell. I might have started with a bit of a "special" offer. Give the first 1000 tests away entirely. You thereby introduce 1000 people to the concept and likely just about as many Dr.s and their clinics (wouldn't the blood work have to be authorized by Docs who would also then be in on the interpretation and results). Then, having been introduced to a powerful new tool, they might be tempted to continue using OvaDx for additional testing and even introduction to new patients. Dr. to patient..."We are working with a new product which is much more fine grained than previous tests....It is expensive but potentially life saving...etc."
Very clever and very novel product introduction. I've got to hand it to them. Free samples to 1000 people all of whom will become part of a large research study.
Way to go Mike. I wonder why Khrystyne Haje? Just another pretty face or a survivor of ovarian cancer? Would be nice if she's both.
And a trade at .34. Nice!
Nice find Mike. An important development indicating progress and perhaps a bit of an update for the troops. At least we know what's happening to OVA Dx - clinical trials.
As far as it's usefulness as a forum, it might be more useful for investors than the general public. If you google "Ovarian Cancer Forum" or "Ovarian Cancer Information" the Arrayit forum doesn't come up in at least the first couple of search pages.
Yet, the information is compact, well developed and useful. The company is alive and well.
Go team!
Amen Mike and Del. I think Arrayit will be coming out of hibernation with a hungry growl rather than a yawn and a stretch. Can always hope!
Good thoughts dr. I too would like to see a little bit more by way of pronouncements. I've had the feeling that they are waiting for the perfect data at the perfect moment and then they'll announce. That moment could be fun.
Good digging once again Silver. ARYC would do well to look into these particular individuals and, likely, part company with them. Never hurts to be squeaky clean.
I don't find the Mabcure news that impressive though it is noteworthy that they've at least published something. I tend to think that Arrayit's work was, even a year or more ago, well beyond what Mabcure announced today. Presumably, in that time ArrayIt has done some additional work which will place them even further in the lead. Better have anyway.
Where's Houston when you need them? Silver, where the heck are you? We need some action around here.
Good point Mike. I wonder if that isn't what is in the works? ARYC would have the advantage in that their work is being done on home soil. It will take a long time before work being done in Thailand and Belgium makes its way to these shores however legitimate the science. Mabcure's pr does speak to the need for expediting things (I'm sure that Arrayit is well aware of that need however).
Thanks Mike. That's perfect. Don't know why my brokerage wouldn't be able to provide the same info but at least we know it's available. Level II looks very interesting. Big gaps and, at the moment, not a lot of sellers.
Well that kind of explains it doesn't it. I don't like the absence of a bid and ask but demand remains solid in anticipation of something..... Price holding and substantial quantities being exchanged. Something has got to be up.
What is OTO Mike? I wondered whether it had gone pink due to a late filing or something of that nature.
Still, shares being tightly held. Not much action but upward pressure. I sense something's in the wind. I'm typically wrong...
Quite a bit of activity yesterday. Dormant as a corpse today. Is it even trading or has it been suspended? I can find no current bid/ask on my Action Direct account which quotes real time info.
I agree Solomon, patience. News when it comes should be good.
Jeesh, I hope things are more hopeful than that Admiral. I have no reason to believe that, despite the lack of news, there is no hope for OvaDx or their other potential pre-symptomatic, diagnostic tools. Indeed, I believe that the company is deliberately waiting on what could effectively be a blockbuster announcement. No more fluff, hence the shortage of news. But when something substantive comes down the pipe, watch out. Or so I would have me believe.
Take care there fella.
Have to agree with many of your sentiments dr. We were supposed to be doing several billion in sales on OvaDx by now according to Houston hype of a year ago.
We all knew the truth wasn't emanating from Houston but we'd still like to know what's up? Where are the trials and what stage does the company find itself in regarding the various diagnostic tests? Couldn't be too hard to put together a little something for the masses.
Good points Mike...that surely would be helpful. Maybe Houston could get that little job done.
.28 - .70 bid ask. Isn't that where we came in? This movie is beginning to loop....
I'm thinking that that's what all this fuss is about - an imminent FDA application. Unless, that is, they've done something on the Parkinson front (like arranged a partner or received a grant). I'm betting on OvaDx though and God speed. I'm about to spend my second Christmas without my wife who passed away from ovarian cancer just over a year ago. It is a terrible disease as there are so few obvious physical symptoms. OvaDx would likely have saved her life if it had been administered as a routine and precautionary predictive test.
Unless of course, even in the prospective trial a certain percentage of known cancer patients have been salted into the trial. Would make more sense than a totally random grouping of women - but does the FDA always make sense?
Thanks Mike. Missed that. The prospective trial is the one that intrigues me. What happens? If OvaDx finds indicators, does the medical profession get to intervene and do follow-up testing for confirmation and treatment or does the disease have to play out in the normal course of affairs (strikes me as totally unethical)? Further, given a trial of that size it is entirely possible that no one in the test population has ovarian cancer given the relatively low incidence of the disease. I'm sure all of this has been factored in but it would be difficult to see absolute reliability unless both positives and negatives were given a significant time frame in which to prove out. I like the retrospective tests better (even with a blind component to it) as time is then factored out.
Bart
Just to clear up any confusion as to which pathway the company is opting for in it's attempts to get approval for Ova Dx. I can't remember seeing this Aug PR but it clearly states that ARYC will be seeking PMA approval. While the PMA (Pre Market Approval) process is more sringent I actually believe it involves fewer hoops. Remember also, that ArrayIt is partnered with DOCRO (March) to bring OvaDx to market. They may be closer than we thought.
SUNNYVALE, Calif., Aug. 23, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC - News), a leader in life sciences and healthcare technology, announces today that the company has chosen the Premarket Approval (PMA) pathway for its OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test. While the standard for a PMA is higher than for a 510(k), the company believes that a PMA OvaDx® submission can achieve a Class III PMA approval, the most stringent approval level granted by the FDA for in vitro diagnostic devices.
Arrayit OvaDx® employs the company's patented and proprietary microarray platform to identify the presence of approximately 100 protein biomarkers in the serum, allowing the detection of ovarian cancer as early as 5 years in advance of any symptoms. Ovarian cancer is known as the "silent killer" because most patients do not report symptoms until the disease has spread beyond the ovaries to other tissues and organs. Early detection greatly improves treatment options and prognosis, such that long-term survivability of early stage patients is about 90% compared to 10% for late stage patients. Arrayit's OvaDx® test will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc.
Arrayit CEO and Chairman Rene Schena states, "We have carefully considered the technical and regulatory issues with respect to OvaDx® and have decided that a PMA submission, though more demanding than a 510(k), is the most appropriate pathway to market for our ovarian cancer screening test. The Premarket Approval process for OvaDx® will provide a basis for product differentiation in the marketplace, and allow us to maximize shareholder value by gaining the market awareness and market share required to detect ovarian cancer earlier and improve the lives of women afflicted with this serious illness."
It would seem that way. I proposed to Silver that he enjoy the moment. Silver has, however, done a lot of digging and made nefarious connections that others haven't, much of that stated in his last several posts. Silver prefers to see the glass half empty, however, so I was just saying lighten up a bit. Otherwise, he does raise some legitimate concerns (though I think he wanders on the dark side a little excessively).
I'm not sure that OvaDx will have to undergo additional FDA trials. To bring it to the point where it is - already remarkably predictive - has meant a large degree and scale of testing of both pre-symptomatic and symptomatic women. I'm not sure what would be gained by years of unnecessary testing when, as a an ovarian cancer test, it would already be far more effective than anything on the market.
I second that!
Doesn't seem like a pump and dump so far Silver. Who is pumping? And who is dumping? I'd like to see something concrete to support the price action - something that we could point to and say "see, a pump.." but I'm not privy to that at the moment and neither is anyone else as far as I can tell. So this seems more speculation based. I still contend that the fundamentals of the company are strong and a .50 price tag is fair value with or without a major announcement.
Hey Silver, take out the party hat and enjoy the moment. You don't have to be such a wet blanket so much of the time.
Bart
It's not going to close under .25 anymore Silver. We're on our way to the Nasdaq. Have no idea how we're going to do that but OvaDx could be the passport. I believe this stock is undervalued at under a buck just based on the current business model let alone prospects for diagnostic tests.
Bid-ask situation has pretty well resulted in a stalemate. Upward pressure for sure...
Interesting bid and ask at the moment .28 - 55. A huge spread, larger than I've seen in recent memory.
Agree dr c6. No matter. We accept all comers here.Indeed, welcome to the board.....
Christmas may be happening. This may simply be anticipation of an announcement or something might be up and those in the know are taking early advantage.
Cheers
Slow steady progress on the price front. You'd have to think there'd be some kind of news release on some front coming - it's been a while. An update on OVA Dx would seem like a likely candidate.
Well put Admiral. I have a major limp myself as a result of IMGG. I'm not sure what hurts most - the loss of money or the loss of faith. I bailed on all fronts on that one as I no longer trust management. What they are being required to do is only what a prudent management would and should have done proactively rather than reactively.
I agree with you as well about Arrayit in that I sense a great deal of promise here in Arrayit-land. I would prefer sooner rather than later but silence to me indicates only that management has too much substantive developmental activity on their plates to be bothering with keeping the masses happy .
It has been awfully quiet for quite a long time. I actually prefer that to fluffy meaningless releases, however. Still, you'd think there must be some positive news ahead. What do you say Admiral after all the bad things at IMGG? You limping a bit?
Coming hard on the heals of $500,000 in orders that's a pretty broad statement Silver. Sounds like there could be a considerable amount of business acumen on board. Things aren't progressing in the big ticket areas as fast as we'd like but, then again, who knows? We're on the company if they disclose too much or too little. I like the present course of quietude - don't speak until you've got something to be speaking about. Would be nice to hear about an FDA submission in the days ahead though.